Suppr超能文献

再灌注床边标志物的血管造影验证

Angiographic validation of bedside markers of reperfusion.

作者信息

Shah P K, Cercek B, Lew A S, Ganz W

机构信息

Division of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California 90048.

出版信息

J Am Coll Cardiol. 1993 Jan;21(1):55-61. doi: 10.1016/0735-1097(93)90716-e.

Abstract

OBJECTIVES

We sought to validate with coronary angiography several primary and ancillary markers of reperfusion.

BACKGROUND

The availability of bedside markers of reperfusion is of major importance in the thrombolytic therapy of acute myocardial infarction. However, the reliability of current markers is still controversial.

METHODS

Changes in chest pain, ST segment elevation and heart rate and rhythm were assessed every 5 to 10 min for up to 3 h after initiation of recombinant tissue-type plasminogen activator therapy in 82 patients with acute myocardial infarction. Coronary angiography was performed within 24 h.

RESULTS

At angiography, 69 of the 82 patients had a patent infarct-related artery with Thrombolysis in Myocardial Infarction trial (TIMI) grade 3 flow and a rapid and progressive decrease in chest pain and ST elevation. The pain resolved in 24 +/- 23 min (range 3 to 50). The ST elevation decreased by > or = 50% within 16 +/- 14 min (range 5 to 41). Accelerated idioventricular rhythm developed in 49% of patients and sinus bradycardia in 23%; conduction abnormalities and atrial fibrillation resolved. All markers appeared in close temporal proximity to the onset of an abrupt increase in plasma creatine kinase (CK) and CK-MB isoenzyme activity, a previously validated marker of the time of reperfusion. Before its final resolution, ST elevation transiently decreased and increased in 58% of patients. Comparison of one pretreatment and one posttreatment electrocardiogram significantly reduced the reliability of ST segment change as a marker of reperfusion. In 13 of 82 patients, the infarct-related artery demonstrated TIMI grade < or = 2 flow; in 9, pain and ST elevation did not lessen and CK and CK-MB activity showed no abrupt increase. The remaining four patients initially demonstrated a decrease in pain and ST elevation; however, within 3 h and before angiography, the recurrence of pain and ST elevation suggested reocclusion.

CONCLUSIONS

A rapid and progressive decrease in pain and ST elevation is a reliable marker of reperfusion with TIMI grade 3 flow. Because ST elevation and pain often fluctuate before undergoing final resolution with reperfusion, frequent or continuous monitoring of ST elevation is essential for reliable recognition of the fact and time of reperfusion. Accelerated idioventricular rhythm and episodes of sudden sinus bradycardia, although specific to reperfusion, do not occur in all patients with reperfusion.

摘要

目的

我们试图通过冠状动脉造影术验证几种再灌注的主要和辅助标志物。

背景

在急性心肌梗死的溶栓治疗中,床旁再灌注标志物的可用性至关重要。然而,目前标志物的可靠性仍存在争议。

方法

在82例急性心肌梗死患者中,启动重组组织型纤溶酶原激活剂治疗后,每5至10分钟评估胸痛、ST段抬高、心率和心律的变化,持续3小时。在24小时内进行冠状动脉造影。

结果

在血管造影时,82例患者中有69例梗死相关动脉通畅,心肌梗死溶栓试验(TIMI)血流分级为3级,胸痛和ST段抬高迅速且逐渐减轻。疼痛在24±23分钟(范围3至50分钟)内缓解。ST段抬高在16±14分钟(范围5至41分钟)内下降≥50%。49%的患者出现加速性室性自主心律,23%的患者出现窦性心动过缓;传导异常和心房颤动消失。所有标志物出现的时间都与血浆肌酸激酶(CK)和CK-MB同工酶活性突然升高的时间密切相关,CK和CK-MB同工酶活性是先前验证的再灌注时间标志物。在最终缓解之前,58%的患者ST段抬高短暂下降然后又上升。比较一次治疗前和一次治疗后的心电图显著降低了ST段变化作为再灌注标志物的可靠性。在82例患者中的13例中,梗死相关动脉显示TIMI血流分级≤2级;在9例中,疼痛和ST段抬高没有减轻,CK和CK-MB活性没有突然升高。其余4例患者最初疼痛和ST段抬高有所减轻;然而,在3小时内且在血管造影之前,疼痛和ST段抬高复发提示再闭塞。

结论

疼痛和ST段抬高迅速且逐渐减轻是TIMI血流3级再灌注的可靠标志物。由于ST段抬高和疼痛在再灌注最终缓解之前经常波动,因此频繁或持续监测ST段抬高对于可靠识别再灌注的事实和时间至关重要。加速性室性自主心律和突发窦性心动过缓发作虽然是再灌注所特有的,但并非所有再灌注患者都会出现。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验